Us Bancorp \De\ Cogent Biosciences, Inc. Transaction History
Us Bancorp \De\
- $78.3 Billion
- Q2 2025
A detailed history of Us Bancorp \De\ transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 31 shares of COGT stock, worth $377. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31
Previous 226
86.28%
Holding current value
$377
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding COGT
# of Institutions
195Shares Held
115MCall Options Held
61.9KPut Options Held
223K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$111 Million4.6% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY8.96MShares$109 Million2.75% of portfolio
-
Commodore Capital LP New York, NY8.89MShares$108 Million5.22% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$88.8 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$84.9 Million10.05% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $802M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...